medigraphic.com
ISSN 1870-6592 (Print)
Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez

2011, Number 1

<< Back Next >>

Enf Neurol (Mex) 2011; 10 (1)

Risk factors for physical health in people with severe mental illness in Mexico

Cruz-Ortiz M, Pérez-Rodríguez MC, Jenaro-Río C, Hernández-Blanco ML, Flores-Robaina N, Vega CV

Language: Spanish
References: 23
Page: 5-10
PDF size: 259.76 Kb.


ABSTRACT

This is a descriptive study of a convenience sample of people with severe mental illness whose aim was to identify physical risk factors and support needs for health care and safety. The main risk factors identified in this study are overweight and obesity in people with severe mental illness, this coupled with the lack of identification of primary caregivers regarding the need for support in promoting healthy lifestyles can increase vulnerability. The study population is a population twice as vulnerable to physical risk factors associated with lifestyles. This vulnerability is due to both the typical evolution of mental illness as poor integration of this group to the preventive health services. Knowledge of these factors contributes to the design of policies and programs that promote comprehensive care of this group.


REFERENCES

  1. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM et al. Physical health monitoring of patients with schizophrenia. 2004: 1334-49.

  2. Kohn R, Levav I, Caldas de Almeida J, Vicente B, Andrade L, Caraveo-Anduaga J, Saxena S, Saraceno B. Los trastornos mentales en América Latina y el Caribe: asunto prioritario para la salud pública. Rev Panam Salud Pública 2005; 18(4/5): 229-40.

  3. WHO. Integrating mental health into primary care: A global perspective. Geneva: World Health Organization; 2008.

  4. Lambert T, Velakoulis D, Pantelis C. Medical comorbidity in schizophrenia. The Medical Journal of Australia 2003; 178: 67-70.

  5. Vreeland B. Bridging the gap between mental and physical health: a multidisciplinary approach. J Clin Psychiatry 2007; 68 (Suppl 4): 26-33.

  6. Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra J, Azorin J. Drawing up guidelines for the attendance of physical health of patients with severe mental illness. Encephale. 2009; 35 (4): 330-9.

  7. Dickey B, Normand S, Weiss R, Drake R, Azeni H. Medical morbidity, mental illness, and substance use disorders. Psychiatric Services 2002; 53 (7): 861-7.

  8. Smith S, Yeomans D, Bushe Ch, Eriksson C, Harrison T, Holmes R, Mynors-Wallis L, Oatway H, Sullivan G. A well-being programme in severe mental illness. Reducing risk for physical ill-health: A post-programme service evaluation at 2 years. European Psychiatry 2007; 22 (7): 413-8.

  9. Bradizza C, Maisto S. Predicting post-treatment-initiation alcohol use among patients with severe mental illness and alcohol use disorders. Journal of Consulting and Clinical Psychology 2009; 77 (6): 1147-58.

  10. Compton M, Daumit G, Druss B. Cigarette smoking and overweight/obesity among individuals with serious mental illnesses: a preventive perspective. Harv Rev Psychiatry 2006; 14 (4): 212-22.

  11. Kessler R. Psychiatric epidemiology. Bulletin of the World Health Organization 2000; 78 (4): 464-74.

  12. Murray C, López A. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge: Harvard School of Public Health on behalf of the World Health Organization and the World Bank 1996.

  13. Murray C, López A. Progress and directions in refining the global burden of disease approach: a response to Williams. Health Economy 2000; 9 (1): 69-82.

  14. Verdugo M, Arias B, Ibáñez A. Escala de Intensidad de Apoyos. Manual (adaptación española del original: Supports Intensity Scale) 2007.

  15. SSA. �Norma Oficial Mexicana NOM-030-SSA2-1999, para la prevención, tratamiento y control de la hipertensión arterial. Secretaría de Salud 1999.

  16. OMS. Informe sobre la salud en el mundo 2008: La atención primaria de salud, más necesaria que nunca. Ginebra: Organización Mundial de la Salud; 2008.

  17. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010; 17(3).

  18. Wahlbeck K, Cheine M, Essali MA. Clozapine versus typical neuroleptic medication for schizophrenia. Cochrane Database Syst Rev 2000; 2.

  19. Calkin C, van de Velde C, Růziková M, Slaney C, Garnham J, Hajek T, O’Donovan C, Alda M. Can body mass index help predict outcome in patients with bipolar disorder? Bipolar Disord 2009; 11 (6): 650-6.

  20. McIntyre R, Konarski J, Misener V, Kennedy S. Bipolar disorder and diabetes mellitus: Epidemiology, etiology, and treatment implications. Ann Clin Psychiatry 2005; 17 (2): 83-93.

  21. Newcomer J. Metabolic syndrome and mental illness. Am J Manag Care 2007; 13(Suppl 7): 170-7.




2020     |     www.medigraphic.com